These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 29978350)

  • 1. [Patent foramen ovale-intervention or pharmaceutical treatment].
    Liebetrau C; Hamm CW
    Internist (Berl); 2018 Sep; 59(9):981-992. PubMed ID: 29978350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
    Wiktor DM; Carroll JD
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patent foramen ovale closure in the management of cryptogenic stroke: a review of current literature and guideline statements.
    Elzanaty AM; Patel N; Sabbagh E; Eltahawy EA
    Curr Med Res Opin; 2021 Mar; 37(3):377-384. PubMed ID: 33460329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
    Mas JL; Derumeaux G; Guillon B; Massardier E; Hosseini H; Mechtouff L; Arquizan C; Béjot Y; Vuillier F; Detante O; Guidoux C; Canaple S; Vaduva C; Dequatre-Ponchelle N; Sibon I; Garnier P; Ferrier A; Timsit S; Robinet-Borgomano E; Sablot D; Lacour JC; Zuber M; Favrole P; Pinel JF; Apoil M; Reiner P; Lefebvre C; Guérin P; Piot C; Rossi R; Dubois-Randé JL; Eicher JC; Meneveau N; Lusson JR; Bertrand B; Schleich JM; Godart F; Thambo JB; Leborgne L; Michel P; Pierard L; Turc G; Barthelet M; Charles-Nelson A; Weimar C; Moulin T; Juliard JM; Chatellier G;
    N Engl J Med; 2017 Sep; 377(11):1011-1021. PubMed ID: 28902593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Closure of the patent foramen ovale (PFO) in cryptogenic stroke].
    Diener HC; Knebel F
    Herz; 2019 Jun; 44(4):304-309. PubMed ID: 30941472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
    Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
    Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
    Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
    Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study.
    Kasner SE; Thomassen L; Søndergaard L; Rhodes JF; Larsen CC; Jacobson J
    Int J Stroke; 2017 Dec; 12(9):998-1004. PubMed ID: 29090661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventional closure vs. medical therapy of patent foramen ovale for secondary prevention of stroke: updated meta-analysis.
    Vukadinović D; Schirmer SH; Vukadinović AN; Ukena C; Scheller B; Mahfoud F; Böhm M
    Clin Res Cardiol; 2019 Feb; 108(2):157-166. PubMed ID: 30051178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent Stroke Reduction with Patent Foramen Ovale Closure versus Medical Therapy Based on Patent Foramen Ovale Characteristics: A Meta-Analysis of Randomized Controlled Trials.
    Garg A; Thawabi M; Rout A; Sossou C; Cohen M; Kostis JB
    Cardiology; 2019; 144(1-2):40-49. PubMed ID: 31574522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
    Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of device closure of patent foramen ovale in patients with cryptogenic stroke.
    Fukutomi M; Wilkins B; Søndergaard L
    J Intern Med; 2020 Oct; 288(4):400-409. PubMed ID: 32812297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta-analysis of randomized controlled trials.
    Kwong JS; Lam YY; Yu CM
    Int J Cardiol; 2013 Oct; 168(4):4132-8. PubMed ID: 23890879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.
    Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials.
    Alushi B; Lauten A; Cassese S; Colleran R; Schüpke S; Rai H; Schunkert H; Meier B; Landmesser U; Kastrati A
    Clin Res Cardiol; 2018 Sep; 107(9):788-798. PubMed ID: 29644412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials.
    Akobeng AK; Abdelgadir I; Boudjemline Y; Hijazi ZM
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):165-173. PubMed ID: 29602258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. close: Closure of patent foramen ovale, oral anticoagulants or antiplatelet therapy to prevent stroke recurrence: Study design.
    Mas JL; Derumeaux G; Amarenco P; Arquizan C; Aubry P; Barthelet M; Bertrand B; Brochet E; Cabanes L; Donal E; Dubois-Randé JL; Durand-Zaleski I; Ernande L; Finet G; Fraisse A; Giroud M; Guérin P; Habib G; Juliard JM; Leys D; Lièvre M; Lusson JR; Marcon F; Michel P; Moulin T; Mounier-Vehier F; Pierard L; Piot C; Rey C; Rodier G; Roudaut R; Schleich JM; Teiger E; Turc G; Vuillier F; Weimar C; Woimant F; Chatellier G;
    Int J Stroke; 2016 Aug; 11(6):724-32. PubMed ID: 27056964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial Septal Aneurysm, Shunt Size, and Recurrent Stroke Risk in Patients With Patent Foramen Ovale.
    Turc G; Lee JY; Brochet E; Kim JS; Song JK; Mas JL;
    J Am Coll Cardiol; 2020 May; 75(18):2312-2320. PubMed ID: 32381162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study.
    Paciaroni M; Agnelli G; Bertolini A; Pezzini A; Padovani A; Caso V; Venti M; Alberti A; Palmiero RA; Cerrato P; Silvestrelli G; Lanari A; Previdi P; Corea F; Balducci A; Ferri R; Falcinelli F; Filippucci E; Chiocchi P; Grandi FC; Ferigo L; Musolino R; Bersano A; Ghione I; Sacco S; Carolei A; Baldi A; Ageno W;
    Cerebrovasc Dis; 2011; 31(2):109-16. PubMed ID: 21088390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.